DEX can reduce the immunosuppression of patients with oral cancer by increasing the percentage of CD3+, CD4+, DCs and CD4+/CD8+ ratio (Huang L et al., 2021). The gene discussed is CD4; the disease is lip and oral cavity carcinoma.